相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial
Makoto Nishio et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
Caicun Zhou et al.
LANCET RESPIRATORY MEDICINE (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
PL02.01 Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study
M. Johnson et al.
Journal of Thoracic Oncology (2021)
Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer A Phase 3 Randomized Clinical Trial
Jie Wang et al.
JAMA ONCOLOGY (2021)
Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial
Shun Lu et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)
Caicun Zhou et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial
Robert Jotte et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)
Yunpeng Yang et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
The preclinical characterization of CS1001, an anti-PD-L1 IgG4 monoclonal antibody and its activity beyond T cell regulation
Juan Zhang et al.
CANCER RESEARCH (2020)
GEMSTONE-302: A phase III study of platinum-based chemotherapy (chemo) with placebo or CS1001, an antiPDL1 antibody, for first-line (1L) advanced non-small cell lung cancer (NSCLC)
C. Zhou et al.
ANNALS OF ONCOLOGY (2020)
Immune Microenvironment Differences Between Squamous and Non-squamous Non-small-cell Lung Cancer and Their Influence on the Prognosis
Xiangjiao Meng et al.
CLINICAL LUNG CANCER (2019)
Management of Immunotherapy-Related Toxicities. Version 1.2019
John A. Thompson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis
Urania Dafni et al.
LUNG CANCER (2019)
Abandoning the Notion of Non-Small Cell Lung Cancer
Valeria Relli et al.
TRENDS IN MOLECULAR MEDICINE (2019)
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials A Systematic Review and Meta-analysis
Yucai Wang et al.
JAMA ONCOLOGY (2019)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer
Mark A. Socinski et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Estimating Survival in Patients With Lung Cancer and Brain Metastases An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA)
Paul W. Sperduto et al.
JAMA ONCOLOGY (2017)
Molecularly Targeted Therapies in Non-Small-Cell Lung Cancer Annual Update 2014
Daniel Morgensztern et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)